These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 26888854)

  • 1. Autoantibody levels in myositis patients correlate with clinical response during B cell depletion with rituximab.
    Aggarwal R; Oddis CV; Goudeau D; Koontz D; Qi Z; Reed AM; Ascherman DP; Levesque MC
    Rheumatology (Oxford); 2016 Jun; 55(6):991-9. PubMed ID: 26888854
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-signal recognition particle autoantibody ELISA validation and clinical associations.
    Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
    Rheumatology (Oxford); 2015 Jul; 54(7):1194-9. PubMed ID: 25524922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biologic predictors of clinical improvement in rituximab-treated refractory myositis.
    Reed AM; Crowson CS; Hein M; de Padilla CL; Olazagasti JM; Aggarwal R; Ascherman DP; Levesque MC; Oddis CV;
    BMC Musculoskelet Disord; 2015 Sep; 16():257. PubMed ID: 26382217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab therapy for myopathy associated with anti-signal recognition particle antibodies: a case series.
    Valiyil R; Casciola-Rosen L; Hong G; Mammen A; Christopher-Stine L
    Arthritis Care Res (Hoboken); 2010 Sep; 62(9):1328-34. PubMed ID: 20506493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.
    Stone KB; Oddis CV; Fertig N; Katsumata Y; Lucas M; Vogt M; Domsic R; Ascherman DP
    Arthritis Rheum; 2007 Sep; 56(9):3125-31. PubMed ID: 17763431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum and clinical significance of myositis-specific autoantibodies in Chinese patients with idiopathic inflammatory myopathies.
    Li S; Ge Y; Yang H; Wang T; Zheng X; Peng Q; Lu X; Wang G
    Clin Rheumatol; 2019 Aug; 38(8):2171-2179. PubMed ID: 30863950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of clinical improvement in rituximab-treated refractory adult and juvenile dermatomyositis and adult polymyositis.
    Aggarwal R; Bandos A; Reed AM; Ascherman DP; Barohn RJ; Feldman BM; Miller FW; Rider LG; Harris-Love MO; Levesque MC; ; Oddis CV
    Arthritis Rheumatol; 2014 Mar; 66(3):740-9. PubMed ID: 24574235
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-transcription intermediary factor 1-gamma autoantibody ELISA development and validation.
    Aggarwal R; Oddis CV; Goudeau D; Fertig N; Metes I; Stephens C; Qi Z; Koontz D; Levesque MC
    Rheumatology (Oxford); 2014 Mar; 53(3):433-7. PubMed ID: 24255164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical implications of autoantibody screening in patients with autoimmune myositis.
    Ghirardello A; Zampieri S; Tarricone E; Iaccarino L; Bendo R; Briani C; Rondinone R; Sarzi-Puttini P; Todesco S; Doria A
    Autoimmunity; 2006 May; 39(3):217-21. PubMed ID: 16769655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
    Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
    J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rituximab in the treatment of inflammatory myopathies: a review.
    Fasano S; Gordon P; Hajji R; Loyo E; Isenberg DA
    Rheumatology (Oxford); 2017 Jan; 56(1):26-36. PubMed ID: 27121778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum levels of B-cell activating factor of the TNF family (BAFF) correlate with anti-Jo-1 autoantibodies levels and disease activity in patients with anti-Jo-1positive polymyositis and dermatomyositis.
    Kryštůfková O; Hulejová H; Mann HF; Pecha O; Půtová I; Ekholm L; Lundberg IE; Vencovský J
    Arthritis Res Ther; 2018 Jul; 20(1):158. PubMed ID: 30053824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of BAFF receptors in muscle tissue of myositis patients with anti-Jo-1 or anti-Ro52/anti-Ro60 autoantibodies.
    Kryštůfková O; Barbasso Helmers S; Venalis P; Malmström V; Lindroos E; Vencovský J; Lundberg IE
    Arthritis Res Ther; 2014 Oct; 16(5):454. PubMed ID: 25301447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Myositis-specific and myositis-associated autoantibody profiles and their clinical associations in a large series of patients with polymyositis and dermatomyositis.
    Cruellas MG; Viana Vdos S; Levy-Neto M; Souza FH; Shinjo SK
    Clinics (Sao Paulo); 2013 Jul; 68(7):909-14. PubMed ID: 23917652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical features of anti-TIF1-α antibody-positive dermatomyositis patients are closely associated with coexistent dermatomyositis-specific autoantibodies and anti-TIF1-γ or anti-Mi-2 autoantibodies.
    Muro Y; Ishikawa A; Sugiura K; Akiyama M
    Rheumatology (Oxford); 2012 Aug; 51(8):1508-13. PubMed ID: 22539482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Longitudinal Course of Disease in a Large Cohort of Myositis Patients With Autoantibodies Recognizing the Signal Recognition Particle.
    Pinal-Fernandez I; Parks C; Werner JL; Albayda J; Paik J; Danoff SK; Casciola-Rosen L; Christopher-Stine L; Mammen AL
    Arthritis Care Res (Hoboken); 2017 Feb; 69(2):263-270. PubMed ID: 27111848
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association of anti-Ro52 autoantibodies with myositis and scleroderma autoantibodies.
    Frank MB; McCubbin V; Trieu E; Wu Y; Isenberg DA; Targoff IN
    J Autoimmun; 1999 Mar; 12(2):137-42. PubMed ID: 10047434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum levels of anti-transcriptional intermediary factor 1-γ autoantibody associated with the clinical, pathological characteristics and outcomes of patients with dermatomyositis.
    Zhang L; Yang H; Yang H; Liu H; Tian X; Jiang W; Peng Q; Wang G; Lu X
    Semin Arthritis Rheum; 2022 Aug; 55():152011. PubMed ID: 35489170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interferon-regulated chemokine score associated with improvement in disease activity in refractory myositis patients treated with rituximab.
    López De Padilla CM; Crowson CS; Hein MS; Strausbauch MA; Aggarwal R; Levesque MC; Ascherman DP; Oddis CV; Reed AM
    Clin Exp Rheumatol; 2015; 33(5):655-63. PubMed ID: 26446265
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased visfatin levels are associated with higher disease activity in anti-Jo-1-positive myositis patients.
    Hulejová H; Kryštůfková O; Mann H; Klein M; Pavlíčková K; Zámečník J; Vencovský J; Šenolt L
    Clin Exp Rheumatol; 2016; 34(2):222-9. PubMed ID: 26886056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.